Atopic dermatitis boasts a large and transformative pipeline, says analyst
The atopic dermatitis (AD) space will see a total transformation over the next decade due to intense clinical activity, says analyst.
According to analytics firm GlobalData, 64% of the pipeline consists of small molecular agents while the rest comprises biologics. Most of these are interleukin inhibitors hoping to follow in the footsteps of Dupixent (dupilumab), which is marketed by France’s Sanofi (Euronext: SAN) and Regeneron (Nasdaq: REGN) and generated 3.5 billion euros ($4.2 billion) sales in 2020, up 73% on 2019,
However, there are some novel drug classes adding flare to the AD pipeline, including sphingosine 1-phosphate receptor (S1PR) modulators and OX40 inhibitors. The latter classes will help diversify the pipeline and act as a catalyst for more innovation in the AD realm.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze